Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
St. Jude Children's Research Hospital AstraZeneca National Institutes of Health (NIH) |
---|---|
Information provided by: | St. Jude Children's Research Hospital |
ClinicalTrials.gov Identifier: | NCT00132158 |
The purpose of this Phase I study is to find the largest dose of the drug irinotecan, in combination with ZD1839, that can be given safely to children and to learn the good and bad effects. Studies performed in the laboratory have shown that ZD1839 helps make available the orally administered irinotecan. In this study the intravenous (given into the vein) formula of irinotecan will be given orally on days 1-5 and days 8-12. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12. Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course 1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Rhabdomyosarcomas Neuroblastoma Osteosarcoma |
Drug: Irinotecan (Camptosar), Gefitinib (Iressa) |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa®) and an Oral Formulation of Irinotecan (Camptosar™) in Children With Refractory Solid Tumors |
Estimated Enrollment: | 30 |
Study Start Date: | September 2005 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 |
Drug: Irinotecan (Camptosar), Gefitinib (Iressa)
See Detailed Description for treatment plan.
|
This is a phase I study to estimate the maximum tolerated dose and the dose limiting toxicities of the intravenous formulation of irinotecan given orally in combination with a fixed dose of oral gefitinib. This trial will use the EWOC method, which is an adaptive dose escalation scheme. The method is fully adaptive and makes use of all the information available at the time of each dose assignment, and directly addresses the ethical need to control the probability of overdosing. It is designed to approach the maximum tolerated dose (MTD) as fast as possible.
In this study the intravenous formulation of irinotecan will be given orally on days 1-5 and days 8-12 (dose level begins at 5 mg/m2 ). One patient will be treated at each dose level of irinotecan until moderate toxicity is observed. At the level where moderate toxicity is observed, the cohort size will be increased to 2 patients. Dosages will then be increased until the development of DLT as guided by the EWOC model. The estimated MTD will be continually reassessed using all data from preceding patients. The toxicity data of all patients enrolled in the trial are used to update the dose-toxicity relationship and to guide the next escalation/de-escalation. The calculation will be carried out with EWOC software. Patients will be enrolled and the dose assigned is determined based on previous participants' toxicity. The dose of ZD1839 will be a fixed dose and will be administered orally on days 1-12 - [150 mg/m2 (maximum 250 mg)] Each course of treatment will consist of 21 days. The administration of irinotecan on day 12 of course
1 and day 2 of course 2 will be an intravenous administration. All other doses and subsequent courses will consist of an orally administered dose.
Secondary Objectives Include:
Ages Eligible for Study: | up to 21 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Lisa M McGregor, MD, PhD | 1-866-278-5833 | info@stjude.org |
United States, Tennessee | |
St. Jude Children's Research Hospital | Recruiting |
Memphis, Tennessee, United States, 38105 | |
Contact: Lisa M McGregor, MD, PhD 866-278-5833 info@stjude.org |
Principal Investigator: | Lisa M McGregor, MD, PhD | St. Jude Children's Research Hospital |
Responsible Party: | St. Jude Children's Research Hospital ( Lisa M McGregor, MD, PhD/Principal Investigator ) |
Study ID Numbers: | POCPZD, IRUSIRES0181 |
Study First Received: | August 17, 2005 |
Last Updated: | April 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00132158 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Glioblastoma Neuroectodermal Tumors, Primitive Astrocytoma Irinotecan Osteosarcoma Neuroblastoma Signs and Symptoms Neuroectodermal Tumors Neoplasms, Connective and Soft Tissue Soft Tissue Sarcomas Malignant Mesenchymal Tumor |
Neoplasms, Germ Cell and Embryonal Sarcoma Neuroepithelioma Osteogenic Sarcoma Glioma Antineoplastic Agents, Phytogenic Gefitinib Neuroectodermal Tumors, Primitive, Peripheral Rhabdomyosarcoma Neoplasms, Glandular and Epithelial |
Glioblastoma Neoplasms, Muscle Tissue Neuroectodermal Tumors, Primitive Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Neoplasms, Nerve Tissue Irinotecan Neuroblastoma Neoplasms, Connective and Soft Tissue Neoplasms, Germ Cell and Embryonal Therapeutic Uses Glioma Rhabdomyosarcoma Neoplasms by Histologic Type |
Astrocytoma Myosarcoma Osteosarcoma Enzyme Inhibitors Pharmacologic Actions Neuroectodermal Tumors Neoplasms Neoplasms, Bone Tissue Sarcoma Neoplasms, Connective Tissue Neoplasms, Neuroepithelial Antineoplastic Agents, Phytogenic Neuroectodermal Tumors, Primitive, Peripheral Neoplasms, Glandular and Epithelial |